AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04163783
Drug: BGB-3111
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
Trial: NCT01264315
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count \>1x109/L without growth factors~* platelet count \>75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart.
Trial: NCT02062177
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
Trial: NCT02062177
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged \> 70.
Trial: NCT01439009
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
Trial: NCT03069768
Drug: Chantix
RxNorm normalized name: Chantix
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Trial: NCT02101606
Drug: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
Trial: NCT00036218
Drug: sumanirole
RxNorm normalized name: Sumanirole
DrugBank: Sumanirole (DB06477)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00036218
Drug: ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03366844
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: checkpoint inhibitor
Trial: NCT00896519
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00896519
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03563248
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan is a drug that is used to lower blood pressure
Trial: NCT03563248
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is an antibody that may cause programmed cell death of cancer cells
Trial: NCT00001761
Drug: Interleukin-10
RxNorm normalized name: interleukin-10
DrugBank: Interleukin-10 (DB12880)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04745442
Drug: Antithrombin + best available treatment
RxNorm normalized name: antithrombin III
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
Trial: NCT03270085
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
Trial: NCT02629393
Drug: ORGN001 (formerly ALXN1101)
RxNorm normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01525511
Drug: A
RxNorm normalized name: Ac
DrugBank: Actinium (DB12860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets
Trial: NCT01525511
Drug: B
RxNorm normalized name: Bk
DrugBank: Berkelium (DB12993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets
Trial: NCT03348683
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
Trial: NCT00397956
Drug: MK0826, ertapenem sodium / Duration of Treatment: 14 Days
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04507217
Drug: Tislelizumab, Carboplatin, Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
Trial: NCT03335124
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
Trial: NCT03335124
Drug: 0.9% Sodium Chloride Injection
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
Trial: NCT03448835
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atezolizumab 1200 mg 5 cycles
Trial: NCT03448835
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin 100 mg/m2 4 cycles
Trial: NCT03448835
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 50 mg/m2 4 cycles
Trial: NCT01483846
Drug: AV-101
RxNorm normalized name: AV-101
DrugBank: AV-101 (DB12878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
Trial: NCT03937986
Drug: Suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of suvorexant maintenance will be determined.
Trial: NCT03937986
Drug: Cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
Trial: NCT01525212
Drug: BMS-929075
RxNorm normalized name: BMS-929075
DrugBank: BMS-929075 (DB14950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension, ≤ 25 mg, Once daily, 3 days
Trial: NCT01525212
Drug: BMS-929075
RxNorm normalized name: BMS-929075
DrugBank: BMS-929075 (DB14950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension, ≤ 100 mg, Once daily, 3 days
Trial: NCT01525212
Drug: BMS-929075
RxNorm normalized name: BMS-929075
DrugBank: BMS-929075 (DB14950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension, ≤ 400 mg, Once daily, 3 days
Trial: NCT01525212
Drug: BMS-929075
RxNorm normalized name: BMS-929075
DrugBank: BMS-929075 (DB14950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
Trial: NCT01525212
Drug: Placebo matching BMS-929075
RxNorm normalized name: BMS-929075
DrugBank: BMS-929075 (DB14950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension, 0 mg, Once daily, 3 days
Trial: NCT01525212
Drug: Placebo matching BMS-929075
RxNorm normalized name: BMS-929075
DrugBank: BMS-929075 (DB14950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
Trial: NCT02641899
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atorvastatin 40 mg on Day 2 and Day 28
Trial: NCT02641899
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lisinopril 20 mg on Day 2 and Day 28
Trial: NCT02641899
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral warfarin 25 mg on Day 2 and Day 28
Trial: NCT02641899
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral digoxin 0.5 mg on Day 2 and Day 28
Trial: NCT03000114
Drug: XIAFLEX
RxNorm normalized name: Xiaflex
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02522910
Drug: BAY 1000394 (Roniciclib) in combination with docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
Trial: NCT00345371
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03957083
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Trial: NCT01223911
Drug: NNC 0151-0000-0000
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
Trial: NCT04354051
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
Trial: NCT02857465
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
Trial: NCT02857465
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
Trial: NCT00435539
Drug: ocriplasmin
RxNorm normalized name: Ocriplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
Trial: NCT00435539
Drug: ocriplasmin
RxNorm normalized name: Ocriplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
Trial: NCT03167619
Drug: Olaparib Oral Product
RxNorm normalized name: olaparib Oral Product
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib 300mg twice daily
Trial: NCT03167619
Drug: Olaparib Oral Product in combination with Durvalumab
RxNorm normalized name: olaparib Oral Product
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib 300mg twice daily plus intravenous durvalumab every 28 days
Trial: NCT04599790
Drug: TACE combined with lenvatinib and sintilimab
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Trial: NCT03493503
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Salbutamol loading dose
Trial: NCT03493503
Drug: Sodium Chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
Trial: NCT02202603
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single oral tablet
Trial: NCT02202603
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous standard injection
Trial: NCT02553603
Drug: Growth Hormone Releasing Hormone (GHRH)
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
Trial: NCT02553603
Drug: Placebo Growth Hormone Releasing Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo GHRH to be given once daily for 10 weeks
Trial: NCT01226667
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly.
Trial: NCT02870673
Drug: XYLOCAINE
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: xylocaine(20mg/ml) 0.5 ml
Trial: NCT00003554
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003554
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04055649
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01416181
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00337532
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
Trial: NCT00337532
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
Trial: NCT02242279
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02085577
Drug: (S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
Trial: NCT02085577
Drug: Isotonic sodium chloride 0.9 percent
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
Trial: NCT02085577
Drug: Paracetamol 1 g
RxNorm normalized name: Paracetamol 1 g oral tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
Trial: NCT02085577
Drug: Morphine Sulphate 1 mg/ml
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
Trial: NCT02085577
Drug: Morphine Sulphate 1 mg/ml
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
Trial: NCT02085577
Drug: Ondansetron 2 mg/ml
RxNorm normalized name: ondansetron 2 MG/ML
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
Trial: NCT02085577
Drug: Morphine Sulphate 1 mg/ml
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
Trial: NCT02308280
Drug: Bortezomib following nonmyeloablative allogeneic transplant
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
Trial: NCT03103399
Drug: Nebicapone
RxNorm normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
Trial: NCT01821963
Drug: Pegylated Interferon Alfa 2a
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose: 180 mcg subcutaneously once weekly.
Trial: NCT01821963
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose: 1,000 mg by mouth daily.
Trial: NCT01821963
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose: 750 mg by mouth 3 times a day.
Trial: NCT00252863
Drug: Budesonide Turbuhaler 200 µg
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00252863
Drug: Fluticasone Discus 250 µg
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00252863
Drug: Formoterol Turbuhaler 4.5 µg
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00252863
Drug: Terbutaline Turbuhaler 0.5 mg
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00252863
Drug: Salbutamol pressurized metered dose inhaler (pMDI) 100 µg
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00252863
Drug: Salmeterol Discus 50 µg
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00252863
Drug: Budesonide/Formoterol Turbuhaler 160/4.5 µg
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00252863
Drug: Fluticasone/Salmeterol Discus 250/50 µg
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no